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A B S T R A C T
Huntington's Disease-Like 2 (HDL2), caused by a CTG/CAG expansion in JPH3 on chromosome 16q24, is the
most common Huntington's Disease (HD) phenocopy in populations with African ancestry. Qualitatively, brain
MRIs of HDL2 patients have been indistinguishable from HD. To determine brain regions most affected in HDL2
a cross-sectional study using MRI brain volumetry was undertaken to compare the brains of nine HDL2, 11 HD
and nine age matched control participants. Participants were ascertained from the region in South Africa with
the world's highest HDL2 incidence. The HDL2 and HD patient groups showed no significant differences with
respect to mean age at MRI, disease duration, abnormal triplet repeat length, or age at disease onset. Overall,
intracerebral volumes were smaller in both affected groups compared to the control group. Comparing the HDL2
and HD groups across multiple covariates, cortical and subcortical volumes were similar with the exception that
the HDL2 thalamic volumes were smaller. Consistent with other similarities between the two diseases, these
results indicate a pattern of neurodegeneration in HDL2 that is remarkably similar to HD. However smaller
thalamic volumes in HDL2 raises intriguing questions into the pathogenesis of both disorders, and how these
volumetric differences relate to their respective phenotypes.
1. Introduction
Huntington's disease like 2 (HDL2) is the most common
Huntington's disease (HD) phenocopy in populations with an African
ancestry and is emerging as the most common HD phenocopy in South
America, the USA and parts of Europe (Margolis et al., 2004; Mariani
et al., 2016; Walker et al., 2018). South Africa has the highest number
of HDL2 cases described despite the under ascertainment of patients
due to lack of resources in rural communities (Anderson et al., 2017b;
Baine et al., 2016).
Huntington's Disease is caused by a CAG/CTG repeat expansion in
exon 1 of the huntingtin gene on chromosome 4p16.3, while HDL2 is
caused by a similarly sized CTG/CAG expansion in exon 2A of juncto-
philin-3 (JPH3) on chromosome 16q24.3 (Holmes et al., 2001). Both are
autosomal dominant disorders characterized by psychiatric disease,
movement disorder and cognitive dysfunction which progress and in-
evitably result in death approximately 15 to 20 years after clinical onset
(Margolis et al., 2001). Observations of the HDL2 phenotype are from
retrospective and anecdotal cases and reviews (Anderson et al., 2017b).
Notwithstanding these genetic differences and the need for systematic
study of the HDL2 clinical phenotype, HDL2 is the disease that has been
described to most resemble HD (Walker et al., 2003).
Furthermore, qualitative MRI studies have not been able to differ-
entiate between HDL2 and HD. To date these rare reports suggest si-
milar patterns of atrophy between these two disorders (Anderson et al.,
2017b). A systematic review of 69 published cases of HDL2 reported 20
MRI scans of HDL2 patients described as indistinguishable from HD
(Anderson et al., 2017b). An exception was a patient with HDL2 who
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presented with parkinsonism and myoclonus. The MRI of this case
showed typical cerebral atrophy but relative sparing of the caudate
nucleus (Bardien et al., 2007). A report of a single case of HDL2 having
two MRIs five years apart described progressive atrophy of the same
areas as seen in HD (Rodrigues et al., 2008). Hyperintense putaminal
rims on T2 imaging have been described in three cases with HDL2 from
the same family (Schneider et al., 2012). The putaminal rim sign has
also been detected in a number of other degenerative movement dis-
orders including Multi-System Atrophy (MSA), Neuro-Acanthocytosis,
Dentatorubral-Pallidoluysian Atrophy (DRPLA) and Spinocerebellar
Ataxia Type 17 (SCA17).
Despite the fact that HD and HDL2 are caused by mutations in
different genes, which are linked to different functions within the cell,
the majority of the qualitative MRI reports, neuropathological analysis,
and clinical phenotype, highlight the similarities between both dis-
orders. We therefore hypothesized that quantitative MRI analysis of
HDL2 patients would reveal similar findings to those detected in HD
patients. To test this hypothesis, we performed a blinded systematic
imaging study of matched HD and HDL2 patients with a normal control
group, taking advantage of the relatively high number of HDL2 cases
that have been reported in the region surrounding Johannesburg, South
Africa (Anderson et al., 2017b; Krause et al., 2015).Comparing the
brain MRIs of these clinically similar diseases has the potential to guide
further investigation into the differences and similarities between HD
and HDL2 and forms part of an ongoing systematic characterization of
the phenotype of HDL2.
2. Methods
Patients with HDL2 and HD were identified and diagnosed through
the Division of Human Genetics, National Health Laboratory Service
and the School of Pathology, The University of the Witwatersrand, in
Johannesburg, South Africa. Controls were unrelated healthy acquain-
tances matched for gender, age and race. Participants were enrolled
between January 2015 and June 2017 and all subjects had African or
mixed ancestry including a significant African component. The Human
Research Ethics Committee of The University of the Witwatersrand
approved this cross-sectional study (M140872).
MRIs of subjects were performed at the University of the
Witwatersrand Donald Gordon Medical Centre Radiology Department
on a 1.5 T Philips Intera MR scanner (Philips Medical Systems,
Eindhoven). There were no relevant scanner upgrades during the study.
The MRI sequences used in this study are available in the supplement.
We used the Brain Research: Analysis of Images, Networks, and
Systems (BRAINS) protocol, which has been validated and extensively
used to measure intracerebral volumes for HD in the large PREDICT-HD
study (Paulsen et al., 2008). Scans were processed by Brain Image
Analysis, LLC using the cross-sectional analysis stream of NeuroAnaly-
tica version 1.3.09, a commercial image analysis platform based on
AutoWorkup (Pierson et al., 2011). A discriminant tissue classification
was then performed (Harris et al., 1999). Artificial neural networks for
each subcortical structure were applied (Powell et al., 2008). Additional
information about this technique is available in the supplement.
Comparison of age at MRI, disease duration, abnormal repeat
length, and age at onset among the groups was performed using a one-
way ANOVA. Comparison of variables among the three groups, con-
trolling for age at MRI and separately, for disease duration, expanded
repeat length, and age of disease onset was performed using a General
Linear Model. Post-hoc comparisons were performed using the Tukey-
Kramer adjustment. The false discovery rate was controlled by the
Benjamini-Hochberg procedure and significance was calculated at
p < .0084. Data analysis was carried out using SAS version 9.4 for
Windows.
3. Results
Images of nine HDL2, 11 HD and nine normal control participants
were included in the study. None of the HDL2 participants were related.
Three of the HD pedigrees each contributed two participants to the
study. There were no significant differences among the groups with
respect to mean age at MRI (F [2,26]= 0.54; p= .59), disease duration
(F [1,18] =0.57; p= .57), abnormal repeat length (F [1,18] =0.18;
p= .18), or age at onset (F [1,18] =0.63; p= .63) (Table 1).
The main aim of the study was to contrast HD and HDL2 MRIs.
Initially a qualitative comparison of MRIs could not distinguish be-
tween both pathologies (see Fig. 1.) The quantitative comparison was
conducted using BRAINS. We conducted an initial comparison between
HD and healthy controls in order to ensure comparability with previous
studies and validation of the present methodology. Subsequently, the
HDL2 group was compared to controls with the objective of providing
the first MRI brain volumetry characterization of HDL2. Lastly, HD and
HDL2 MRIs were compared.
3.1. Comparison between patients with HD and normal controls
When compared to the normal control group and controlling for the
age at the time of the MRI, the HD group showed significant less grey
matter volume in both of the parietal and left temporal lobes with
significantly smaller caudate nuclei, putamen and globus pallidum bi-
laterally (see Figs. 2 and 3 and Table 1b). These smaller grey matter
volumes were reflected in corresponding increases in CSF volumes
(Fig. 4). Notably the mean thalamic volumes were not statistically
different between the HD group and the normal control group
(p < .01) (see Table 2).
Table 1
Table showing subject demographic data and MRI volumes. a. Subject ages, age
of disease onset, duration of disease and triplet repeat length. b. Unadjusted
volumetric analysis of selected subcortical structures, hippocampi and total
intracranial volumes in cm3. HD=Huntington's Disease, HDL2=Huntington's




Number of participants 9 11 9
Male: Female 5:4 6:5 5:4
Mean (SD) Mean (SD) Mean (SD)
Age at MRI (years) 47.6 (9.1) 46.0 (12.4) 42.6 (9.1)
Abnormal repeat length (n) 47.0 (3.5) 44.9 (3.2) –
Duration of disease (years) 5.6 (3.0) 6.6 (4.8) –
Age at onset(years) 42.0 (10.2) 39.4 (13.1) –
1b Region Volume (cm3) Mean (SD) Mean (SD) Mean (SD)
Left thalamus 5.156 (0.671) 6.453 (0.868) 6.628 (0.698)
Right thalamus 4.885 (0.805) 6.232 (0.745) 6.269 (0.643)
Left putamen 2.147 (0.452) 2.615 (0.233) 4.771 (0.637)
Right putamen 2.249 (0.389) 2.698 (0.263) 4.714 (0.502)
Left caudate 1.010 (0.455) 1.528 (0.485) 3.359 (0.548)
Right caudate 1.080 (0.475) 1.667 (0.488) 3.392 (0.629)
Left globus pallidus 0.812 (0.190) 0.749 (0.103) 1.297 (0.311)
Right globus pallidus 0.772 (0.150) 0.766 (0.101) 1.371 (0.323)
Left amygdala 0.747 (0.230) 0.743 (0.143) 0.841 (0.171)
Right amygdala 0.665 (0.170) 0.755 (0.141) 0.834 (0.266)
Left nucleus accumbens 0.159 (0.050) 0.174 (0.043) 0.266 (0.075)
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Fig. 1. Qualitative MRI Comparison. Three T1 axial 1.5 T MRIs comparing HDL2, HD and a normal control case. Image 1: 35-year-old HD subject with abnormal HTT
allele= 49 triplet repeats. Image 2: 32-year-old HDL2 subject with abnormal JPH3=53 triplet repeats. Image 3: 32-year-old normal control subject. The HDL2 and
HD subjects show qualitatively similar grey and white matter atrophy with caudate nuclei and putaminal volume loss compared to the normal control.
Fig. 2. HD, HDL2 and control groups grey matter and white matter volumes. The estimated least-squares (LS) means from the regression are depicted in a three-way
comparison of grey and white matter volume. Error bars denote the 95% confidence intervals for the mean. Significance was set at p < .008. Symbols denote
significant differences: **: HD, HDL2 < Control; *: HDL2 < Control; $: HD, Control<HDL2. GM=grey matter, WM=white matter.
D.G. Anderson et al. NeuroImage: Clinical 21 (2019) 101666
3
3.2. Comparison between HDL2 and normal controls
Grey matter volume tended to be less in the HDL2 group compared
to control groups when controlling for age at the time of the MRI (see
Fig. 2). The HDL2 group showed significantly smaller grey matter vo-
lumes for both the parietal and temporal lobes and left occipital lobe
and significantly smaller white matter volumes for both the frontal and
occipital lobes and left parietal lobe compared to the normal control
participants (p < .008). Almost all of the CSF spaces were significantly
larger in the HDL2 group compared to the control group (see Fig. 4).
Most of the basal ganglia including the thalamus were significantly
smaller in the HDL2 group compared to the control group (p < .008)
(see Table 1b and Fig. 3).
3.3. Comparison between HDL2 and HD
When comparing the HDL2 and HD groups, a similar pattern of grey
and white matter volume was noted (see Fig. 2). The mean volumes of
the caudate nucleus, globus pallidum, amygdala and the nucleus ac-
cumbens tended to be smaller in the HDL2 group compared to the HD
group but this did not reach statistical significance when compared
across all covariates (Table 1b and Fig. 3). When controlling for age at
the time of the MRI, duration of disease, abnormal repeat length and
age of onset, the HDL2 groups mean thalamic volumes were sig-
nificantly smaller compared to the HD participants (Mean [STD] left
and right thalamic volumes; HDL2= left 5.156 cm3 [0.671],
right= 4.885 cm3 [0.805], HD left= 6.453 cm3 [0.86],
right= 6.232 cm3 [745]).
The HDL2 volumes were smaller when evaluating differences in the
unadjusted putamen volumes in HDL2 and HD cases (Mean [STD] left
and right putamen volumes; HDL2= left 2.147 cm3 [0.452],
right= 2.249 cm3 [0.389], HD left= 2.615 cm3 [0.233],
right= 2.698 cm3 [0.263]). However, when applying the Benjamini-
Hochberg procedure and applying a p < .0084, significance was not
seen bilaterally for the putamen as was with the thalamus when con-
trolling for age of onset. Furthermore, the thalamus (Left: p < .0012,
Right: p < .0006) in comparison to the putamen (Left: p < .011,
Right: p < .0081) had greater significant volume difference between
the two diseases when controlling for age of disease onset (Table 2).
The unadjusted left and right caudate volumes suggest similar
trends as seen in the thalamus and putamen when the unadjusted data
are observed with the HDL2 volumes being smaller compared to the HD
group caudate volumes (Mean [STD] left and right putamen volumes;
HDL2= left 1.010 cm3 [0.455], right= 1.080 cm3 [0.475], HD
left= 1.528 cm3 [0.485], right= 1.667 cm3 [0.488]) (Table 1b).
However, the LS mean caudate volumes are small: 3.2 for HD and 2.2
for the HDL2 groups and when applying the same procedure the dif-
ference between the HDL2 and HD caudate volumes did not reach
significance when controlling for any of the covariates as noted in
Table 2.
The relationship between duration of disease, abnormal repeat
length, age at onset was separately determined for each volume mea-
surement in both the HDL2 and HD groups. The trend was an inverse
correlation for most measurements, as expected, but significance was
not reached. In both diseases smaller volumes of the grey matter
structures was seen with increasing duration of disease and larger re-
peat lengths.
Lastly, on blinded clinical review T2 images demonstrated bilateral
putaminal rim hyperintensities in HD and HDL2 patients, but not in the
control group.
Fig. 3. HD, HDL2 and control groups basal ganglia,
thalamic and hippocampal volumes. The estimated
least-squares (LS) means from the regression are
depicted in the figure in a three-way comparison
among HD, HDL2 and control groups. Statistical
significance is denoted by a symbol. Error bars de-
note the 95% confidence interval for the mean.
Significance was set at p < .008. Symbols: **: HD,
HDL2 < Control, ^: HDL2 < HD < Control, ^^:
HDL2 < Control, HD where significance was
reached. LS= Least-squares means, Nucleus
acc=Nucleus accumbens.
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4. Discussion
This is the first quantitative volumetric MRI study in patients with
HDL2 and the first comparison to a HD group and an unaffected control
group and done blind to the patients diagnosis. Consistent with the
previously reported qualitative review of individual cases (Anderson
et al., 2017b; Margolis et al., 2001). The analysis indicated similar
atrophy of the grey and white matter structures including the basal
ganglia and enlarged CSF spaces in the two disease groups compared to
the normal control group. However, smaller thalamic volumes were
noted in the HDL2 group compared to the HD group. There was no
evidence of relative caudate sparing, as observed in one previous HDL2
case (Bardien et al., 2007).
The HD group showed white and grey matter loss, enlarged CSF
spaces, and basal ganglia changes that replicated the findings of pre-
vious studies using similar analytic methods but much larger sample
Fig. 4. HD, HDL2 and control cerebrospinal fluid
and total intracranial volumes. The estimated least-
squares (LS) means from the regression are depicted
in the graph in a three-way comparison among the
HD, HDL2 and control groups showing cerebrospinal
fluid volumes and total intracranial volumes. Note
that total intracranial volume was divided by 20 to
fit to the graph scale. Statistical significance is shown
with a symbol. Error bars denote the 95% confidence
interval for the mean and significance was set at
p < .008. Symbols denote #: Control<HD <
HDL2. ##: HD, HDL2 < Control where significance
was reached. LS= least squares mean,
CSF=Cerebrospinal fluid.
Table 2
Table comparing the Huntington's Disease Like 2, Huntington's Disease and the Normal control groups basal ganglia mean volume significant differences across
multiple covariates (controlling for age at MRI, controlling for duration of disease, controlling for abnormal repeat length and controlling for age at onset) Two-tailed
significance: P < .008. G. pallidus=Globus Pallidus, HDL2=Huntington's Disease Like 2, HD=Huntington's Disease, N. Accumbens=Nucleus accumbens.
Region Comparison between HDL2, HD and control
groups controlling for age at MRI
Comparison between HDL2 and
HD groups controlling for
duration of disease
Comparison between HDL2 and
HD groups controlling for
abnormal repeat length
Comparison between HDL2 and
HD groups controlling for age at
onset







Left Thalamus HDL2 < HD, Control 0,0007 HDL2 < HD 0,0015 HDL2 < HD 0,0049 HDL2 < HD 0,0012
Right Thalamus HDL2 < HD, Control 0,0005 HDL2 < HD 0,0008 HDL2 < HD 0,0032 HDL2 < HD 0,0006
Left Putamen HDL2, HD < Control < 0.0001 HDL2 < HD 0,0083 HDL2 < HD 0,0063 Not Significant 0,011
Right Putamen HDL2 < HD < Control < 0.0001 HDL2 < HD 0,0064 HDL2 < HD 0,0014 HDL2 < HD 0,0081
Left Caudate HDL2, HD < Control < 0.0001 Not Significant 0,023 Not Significant 0,027 Not Significant 0,034
Right Caudate HDL2, HD < Control < 0.0001 Not Significant 0,010 Not Significant 0,018 Not Significant 0,019
Left G. pallidus HDL2, HD < Control < 0.0001 Not Significant 0,45 Not Significant 0,41 Not Significant 0,42
Right G. Pallidus HDL2, HD < Control < 0.0001 Not Significant 0,81 Not Significant 0,80 Not Significant 0,97
Left Amygdala Not Significant 0,11 Not Significant 0,35 Not Significant 0,27 Not Significant 0,35
Right Amygdala Not Significant 0,27 Not Significant 0,22 Not Significant 0,16 Not Significant 0,25
Left N. Accumbens HDL2, HD < Control 0,0016 Not Significant 0,38 Not Significant 0,16 Not Significant 0,54
Right N.
Accumbens
Not Significant 0,011 Not Significant 0,018 Not Significant 0,10 Not Significant 0,10
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sizes and provides support for the methods and patient population used
in this study (Paulsen et al., 2008; Tabrizi et al., 2009; van den Bogaard
et al., 2011). The key finding of this analysis is the similarity between
the MRIs of HD and HDL2 patients, with the notable exception that the
average thalamic volume was 21% smaller in the HDL2 group com-
pared to the HD group. In contrast to this difference, the mean thalamic
volume in the HD group was similar to those recorded in the normal
control participants.
Initial neuroimaging studies found no difference in thalamic vo-
lumes between HD patients and controls (Rosas et al., 2003). Later
studies have demonstrated thalamic volume loss in HD but have sug-
gested that this reflects disease progression. Studies comparing MRI
brain volumes in HD with normal controls often used different volu-
metric methods and showed HD thalamic volumes being between 2 and
8% less than the unaffected control groups (Coppen et al., 2018;
Kassubek et al., 2004). Thalamic atrophy in HD appears to reflects
whole brain atrophy and is proportional to overall degeneration (van
den Bogaard et al., 2011). Therefore in keeping with previous reports of
HD thalamic volumes, the mean thalamic volumes of the HD group in
this study was 2% less than the control group. However, in the HD and
HDL2 groups, regions like the putamen and caudate showed typically
smaller volumes compared to the normal control group as has been
described previously in HD (Tabrizi et al., 2009; van den Bogaard et al.,
2011). The striking finding from this study was that HDL2 thalamic
volume was significantly smaller than in the HD group when control-
ling for age at the time of the MRI, duration of disease, abnormal repeat
length and age of onset of disease.
Attempts to find features differentiating HDL2 from HD are avail-
able, but findings have been anecdotal, inconsistent or disproved. For
example, the hypothesis that HDL2 is a neuroacanthocytosis syndrome
was recently refuted by a blinded controlled study (Anderson et al.,
2017a). Descriptions of the HDL2's phenotype have introduced the
possibility that HDL2 may disproportionately present with bradyki-
netic/parkinsonian features which likely reflects the unique phenotype
and relatively long expanded repeat length, but this remains unverified
(Margolis et al., 2001)(Schneider et al., 2012). The characterization of
the clinical phenotype of HDL2 will remain incomplete while based
only on retrospective case series (Anderson et al., 2017b). Thus, future
research is needed, and our findings regarding the differences in tha-
lamic volumes between HDL2 and HD may provide a new and exciting
guide to explore into differentiating between these two mutations.
The possible clinical implications and pathogenic mechanisms
causing greater thalamic atrophy in HDL2 would need to be accounted
for. The pathogenesis of HDL2 is complex, with likely contributions
from toxic properties of JPH3 RNA with the repeat expansion, loss of
expression of JPH3, and perhaps expanded tracts of polyglutamine
expressed from a cryptic gene on the antisense strand at the HDL2 locus
(Rudnicki et al., 2007; Seixas et al., 2012; Wilburn et al., 2011). The
finding of smaller putamen and thalamic volumes in HDL2 compared to
HD suggests differential neuronal and/or glial vulnerability in these
areas to the HDL2 mutation compared to the HD mutation. This may
have implications first in terms of phenotype. It has been suggested that
there are clinical differences such as more myoclonus and parkinsonism
although this needs further validation (Anderson et al., 2017b; Margolis
et al., 2001). Secondly although little difference has been reported in
the gross or histopathological findings between five patients with HDL2
compared to matched cases with HD (Rudnicki et al., 2008), it is pos-
sible that the thalamic differences may be the consequence of histo-
pathological discrepancies between these mutations that require larger
samples of HDL2 specimens (Rudnicki et al., 2008).
This study is based on the uniquely high prevalence of HDL2 in
South Africa, and would be difficult to accomplish in any other loca-
tion. Even in this region HDL2 is a rare disorder and therefore the
sample size is small. The results do however establish the general
neuroradiological similarity of HD and HDL2 and are consistent with
their reportedly analogous clinical phenotypes. The selectively smaller
thalamic volumes in HDL2 is an interesting finding, but the sample size
imposes limits on data interpretation. In both HD and HDL2, the re-
lationship between intracerebral volumes and duration of disease and
abnormal repeat length do not reach significance, though most mea-
surements trend to show smaller volumes with increasing duration of
disease and larger abnormal repeat lengths. These are well established
negative correlations for HD demonstrated in larger studies (Tabrizi
et al., 2009). We would predict that in HDL2, like HD, these trends
would be confirmed with larger cross-sectional cohorts of patients or
with longitudinal analyses of smaller cohorts. In support of this, se-
quential MRIs five years apart have been reported for a single HDL2
case which qualitatively demonstrated progressive brain atrophy in a
similar pattern to HD (Rodrigues et al., 2008).
Lastly, we found putaminal rim hyperintensities in all of the HD and
HDL2 cases. This sign has been described before in HDL2 (Schneider
et al., 2012). Other neurodegenerative disorders and normal controls
have been shown to have putaminal rim hyperintensities and this is
therefore unlikely to help distinguish HDL2 from other conditions (Lee
et al., 2005; Tha et al., 2012). To our knowledge, the putaminal rim
sign has not been commented on in HD previously.
5. Conclusion
Huntington's disease like 2 and HD are remarkably similar clinically
and radiologically. When HDL2 is objectively compared to a HD group
that is matched for age, abnormal repeat length and duration of disease
there is a similar pattern emerging of smaller volumes in the grey and
white matter as well as in the basal ganglia. The results presented here,
now demonstrate the similarities between HDL2 and HD extend to
spatial patterns of neurodegeneration, with the interesting exception of
the thalamus, where selective thalamic volume loss tends to be greater
in HDL2.
These findings raise intriguing possibilities about both the con-
vergent and the divergent pathogenic pathways of the two diseases and
opens future paths of research into how this relates to their phenotypes.
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